Yue Liu, PhD

CEO at Ab Studio Inc.

Speaker

Dr. Yue Liu is a serial entrepreneur and the CEO of Ab Studio Inc., with extensive experience at the intersection of cancer biology, neurodegenerative diseases, and regenerative medicine. She has proven expertise in pioneering the development of new therapeutic antibodies and is a leader in AI/computer-aided therapeutic antibody discovery, design, and optimization. Since 2018, Dr. Liu and her team have developed multiple therapeutic antibody candidates, successfully advancing one bi-specific and one tri-specific antibody to the clinical stage. Through computer-aided design, her team also invented a novel Fc-enabled T-cell engager (TCE) platform, with patents allowed in the U.S. and China. As proof of concept, the first Fc+ TCE invented at ABS, a CD20/CD3 bispecific antibody, demonstrated a promising safety and efficacy balance in NHL patients. This asset was recently licensed by Candid Therapeutics as CND261 and will be further studied in the I&I field.

Dr. Liu holds a Ph.D. in cancer biology from Université de Sherbrooke, Quebec, Canada; a Master's degree in internal medicine from Soochow University, China; and a Bachelor's degree in biology from Nanjing University, China. She is the inventor of multiple patents, including those related to the BMS Tau program and the Novo Nordisk ATTR program, and has authored numerous scientific publications.